-
Something wrong with this record ?
Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect
N. Janikashvili, C. Gérard, M. Thébault, A. Brazdova, C. Boibessot, C. Cladière, M. Ciudad, H. Greigert, S. Ouandji, T. Ghesquière, M. Samson, S. Audia, P. Saas, B. Bonnotte
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2020
PubMed Central
from 2012
Europe PubMed Central
from 2012 to 1 year ago
Taylor & Francis Open Access
from 2020-01-01
- MeSH
- Leukemia * MeSH
- Leukocytes, Mononuclear MeSH
- Humans MeSH
- Monocytes MeSH
- Mice, Inbred NOD MeSH
- Mice, SCID MeSH
- Mice MeSH
- Graft vs Host Disease * prevention & control MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Background: Immunosuppressive cell-based therapy is a recent strategy for controlling Graft-versus-Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft-versus-Leukemia (GvL) effect. We have previously reported on a novel subset of human monocyte-derived suppressor cells (HuMoSC) as a prospective approach for controlling GvHD.Objective. The objective of this study was to explore the therapeutic relevance of the HuMoSC in clinical conditions.Methods: Immune regulatory functions of HuMoSC were assessed in inflammatory conditions and in the presence of immunosuppressants. The therapeutic efficiency of the association of HuMoSC with immunosuppressants was evaluated in an experimental model of GvHD induced by human PBMC in NOD/SCID/IL2-Rγc-/- (NSG) mice. Interestingly, the inhibitory functions of HuMoSC against T lymphocytes and their ability to polarize Treg are preserved, in vitro, in inflammatory environments and are not affected by immunosuppressive agents. In vivo, the association of HuMoSC-based treatment with an immunosuppressive drug showed a synergistic effect for controlling GvHD. Furthermore, HuMoSC control GvHD while preserving GvL effect in a xeno-GvHD conditioned mouse model with cell neoplasm (CAL-1). HuMoSC are generated according to good manufacturing practices (GMP) and we demonstrated that these cells tolerate long-term preservation with unaltered phenotype and function.Conclusion.HuMoSC-based therapy represents a promising approach for controlling GvHD and could be quickly implemented in clinical practice.
Department of Immunology Faculty of Medicine Tbilisi State Medical University Tbilisi Georgia
Department of Internal Medicine University Hospital Dijon France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026063
- 003
- CZ-PrNML
- 005
- 20230519085755.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/2162402X.2021.1880046 $2 doi
- 035 __
- $a (PubMed)33659098
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Janikashvili, Nona $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Immunology, Faculty of Medicine, Tbilisi State Medical University (TSMU), Tbilisi, Georgia
- 245 10
- $a Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect / $c N. Janikashvili, C. Gérard, M. Thébault, A. Brazdova, C. Boibessot, C. Cladière, M. Ciudad, H. Greigert, S. Ouandji, T. Ghesquière, M. Samson, S. Audia, P. Saas, B. Bonnotte
- 520 9_
- $a Background: Immunosuppressive cell-based therapy is a recent strategy for controlling Graft-versus-Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft-versus-Leukemia (GvL) effect. We have previously reported on a novel subset of human monocyte-derived suppressor cells (HuMoSC) as a prospective approach for controlling GvHD.Objective. The objective of this study was to explore the therapeutic relevance of the HuMoSC in clinical conditions.Methods: Immune regulatory functions of HuMoSC were assessed in inflammatory conditions and in the presence of immunosuppressants. The therapeutic efficiency of the association of HuMoSC with immunosuppressants was evaluated in an experimental model of GvHD induced by human PBMC in NOD/SCID/IL2-Rγc-/- (NSG) mice. Interestingly, the inhibitory functions of HuMoSC against T lymphocytes and their ability to polarize Treg are preserved, in vitro, in inflammatory environments and are not affected by immunosuppressive agents. In vivo, the association of HuMoSC-based treatment with an immunosuppressive drug showed a synergistic effect for controlling GvHD. Furthermore, HuMoSC control GvHD while preserving GvL effect in a xeno-GvHD conditioned mouse model with cell neoplasm (CAL-1). HuMoSC are generated according to good manufacturing practices (GMP) and we demonstrated that these cells tolerate long-term preservation with unaltered phenotype and function.Conclusion.HuMoSC-based therapy represents a promising approach for controlling GvHD and could be quickly implemented in clinical practice.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a nemoc štěpu proti hostiteli $x prevence a kontrola $7 D006086
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a leukemie $7 D007938
- 650 _2
- $a leukocyty mononukleární $7 D007963
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední NOD $7 D016688
- 650 _2
- $a myši SCID $7 D016513
- 650 _2
- $a monocyty $7 D009000
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gérard, Claire $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Internal Medicine, University Hospital, Dijon, France
- 700 1_
- $a Thébault, Marine $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Brázdová, Andrea $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $7 ntk2015859863
- 700 1_
- $a Boibessot, Clovis $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Cladière, Claudie $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Ciudad, Marion $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Greigert, Hélène $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Ouandji, Séthi $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France
- 700 1_
- $a Ghesquière, Thibault $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Internal Medicine, University Hospital, Dijon, France
- 700 1_
- $a Samson, Maxime $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Internal Medicine, University Hospital, Dijon, France
- 700 1_
- $a Audia, Sylvain $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Internal Medicine, University Hospital, Dijon, France
- 700 1_
- $a Saas, Philippe $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Besançon, France
- 700 1_
- $a Bonnotte, Bernard $u Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Dijon, France $u Department of Internal Medicine, University Hospital, Dijon, France
- 773 0_
- $w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 10, č. 1 (2021), s. 1880046
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33659098 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20230519085748 $b ABA008
- 999 __
- $a ok $b bmc $g 1714931 $s 1146570
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 10 $c 1 $d 1880046 $e 20210219 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079
- LZP __
- $a Pubmed-20211013
